Bioverativ Therapeutics, Inc.
All Topics
Find news about people
Find news on alumni of any org
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


Change Feed
Bioverativ Therapeutics, Inc.
... therapies. The study is being performed under the collaboration agreement with Bioverativ Therapeutics Inc. The development of antibodies (inhibitors) that neutralise the effect of factor ...
... Bioverativ has announced that the FDA has accepted the company's Investigational New Drug ...
... sales for our hemophilia products, ELOCTATE and ALPROLIX, as the spin-off of Bioverativ is expected to complete on February 1, 2017.GAAP guidance includes the minimum ...
... is part of Biogen's hemophilia business, which is expected to launch as Bioverativ on February 1, 2017 as an independent, public company focused on the ...
... will be live on Thursday, January 5, 2017 at 4:00p.m. ET. Additionally, Bioverativ, the planned spin-off of Biogen's hemophilia business, will present as well. That ...
... zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ. "Our collaboration with Biogen has been very successful, and we are delighted ...
Want to see the full history on Bioverativ Therapeutics, Inc.? Upgrade to RelSci Pro now!
Start My Free Trial